The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model

Abstract

Intraoperative autologous whole-cell vaccination is practicable and proved to have anti-tumor potential, and therefore, it could be an additional option in adjuvant cancer therapy.

Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity

“…However, systemic application of IL-12 in the clinic is hindered by its severe toxicity (Cohen 1995;Leonard et al 1997;Car et al 1999). Studies using direct injection of IL-12 into lesions or attempting the genetic manipulation of various tumour cells, T cells or DC cells to produce IL-12 in situ have not been fruitful (Simpson-Abelson et al 2009;Seo et al 2011;Dietrich et al 2012;Kerkar et al 2013;Tan et al 2013). Clearly, the requirements of an effective clinical treatment cannot be satisfied using local strategies, as many clinical tumours are inaccessible or invisible.…”